Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture t (BNCT) by Michiue, Hiroyuki et al.
Journal of Controlled Release 330 (2021) 788–796
Available online 11 November 2020
0168-3659/© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Self-assembling A6K peptide nanotubes as a 
mercaptoundecahydrododecaborate (BSH) delivery system for boron 
neutron capture therapy (BNCT) 
Hiroyuki Michiue a,*, Mizuki Kitamatsu b, Asami Fukunaga c, Nobushige Tsuboi d, 
Atsushi Fujimura c, Hiroaki Matsushita c, Kazuyo Igawa a, Tomonari Kasai a, Natsuko Kondo e, 
Hideki Matsui a,c, Shuichi Furuya a 
a Neutron Therapy Research Center, Okayama University, Japan 
b Department of Applied Chemistry, Kindai University, Japan 
c Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 
d Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan 
e Institute for Integrated Radiation and Nuclear Science, Kyoto University, Japan   
A R T I C L E  I N F O   
Keywords: 
Malignant brain tumor 
Boron neutron capture therapy (BNCT) 
Peptide nanotube 
Boron drug 
Drug delivery system (DDS) 
A6K peptide 
A B S T R A C T   
Boron neutron capture therapy (BNCT) is a tumor selective therapy, the effectiveness of which depends on 
sufficient 10B delivery to and accumulation in tumors. In this study, we used self-assembling A6K peptide 
nanotubes as boron carriers and prepared new boron agents by simple mixing of A6K and BSH. BSH has been 
used to treat malignant glioma patients in clinical trials and its drug safety and availability have been confirmed; 
however, its contribution to BNCT efficacy is low. A6K nanotube delivery improved two major limitations of 
BSH, including absence of intracellular transduction and non-specific drug delivery to tumor tissue. Varying the 
A6K peptide and BSH mixture ratio produced materials with different morphologies—determined by electron 
microscopy—and intracellular transduction efficiencies. We investigated the A6K/BSH 1:10 mixture ratio and 
found high intracellular boron uptake with no toxicity. Microscopy observation showed intracellular localization 
of A6K/BSH in the perinuclear region and endosome in human glioma cells. The intracellular boron concen-
tration using A6K/BSH was almost 10 times higher than that of BSH. The systematic administration of A6K/BSH 
via mouse tail vein showed tumor specific accumulation in a mouse brain tumor model with immunohisto-
chemistry and pharmacokinetic study. Neutron irradiation of glioma cells treated with A6K/BSH showed the 
inhibition of cell proliferation in a colony formation assay. Boron delivery using A6K peptide provides a unique 
and simple strategy for next generation BNCT drugs.   
1. Introduction 
Current advanced cancer therapy includes surgery, chemotherapy, 
and radiation therapy; however, glioblastoma multiforme (GBM) re-
mains the most treatment-resistant malignant primary brain tumor, with 
a median survival of approximately 1.5 years [1]. Most anti-cancer 
drugs—including molecular targeted drugs—used in the treatment of 
various cancers are ineffective for GBM owing to the presence of the 
blood–brain barrier and various other brain specific challenges [2]. 
Therefore, the development of novel anti-GBM treatments with com-
bined drug and radiotherapy is a promising approach for treatment for 
GBM after surgery, particularly for elderly patients [3]. Boron neutron 
capture therapy (BNCT) is one of the most promising GBM treatments. 
BNCT is based on the neutron capture and fission reactions that 10B 
atoms undergo with low-energy neutrons on the irradiation of brain 
tumor tissues with thermal or epithermal neutron beams [4]. The BNCT 
reaction involves high-energy transfer alpha particles (4He) and 7Li 
nuclei with particle ranges that are approximately within the size of the 
cell diameter (<10 μm) [5]. Upon neutron irradiation, only GBM cells 
containing 10B are killed by the boron neutron reaction, while the sur-
rounding normal cells remain unaffected. BNCT is therefore an ideal 
cell-targeting radiotherapy [6]. BNCT has been applied to several 
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obstinate malignancies including GBM, head and neck cancer, mela-
noma, hepatic cancers, and lung cancers, among others [7]. The thera-
peutic efficacy of BNCT depends on the tumor specific boron uptake and 
abundant neutron irradiation of the tumor area [8,9]. Recently, the 
neutron source used for BNCT has been changed to an accelerated 
neutron source that can be installed in hospitals, which eliminates the 
need for a reactor neutron source [10]. One of the greatest challenges in 
BNCT has been developing new boron drugs for application to several 
malignant tumors—in addition to BPA [11]. BPA (4‑borono-L-phenyl-
alanine) is the leading BNCT boron drug for treating malignant mela-
noma and is based on an amino acid analogue fused boron. Many 
researchers have reported that L-amino acid transporter-1 (LAT-1)— 
expressed in many malignant tumor cell lines and cancer tissues—im-
ports BPA into malignant tumor cells [12,13]. BSH (disodium 
undecahydro-mercapto-closo-dodecacarborate) has been used in com-
bination with BPA for treatment of primary malignant glioma BNCT 
[14] and the combination led to significantly longer survival outcomes 
compared with those for BNCT with BPA only [15]. BPA is of course a 
leading player in BNCT, however a limitation of BPA is that the 
expression of LAT-1 in cancer tissue is non-uniform and the intracellular 
uptake of BPA is inhomogeneous. Therefore, new boron drugs with 
different intracellular uptake pathways for combined use with BPA are 
essential for developing BNCT efficacy [16]. 
Drug delivery systems (DDS) for boron agents, including polymeric 
macromolecule DDS such as liposomes and emulsions, which combine 
BSH and several boron compounds, are interesting and adaptable tools 
in preclinical BNCT experiments [17]. In this work, we focused on a 
peptide DDS using A6K peptide [18]. A6K comprises six alanine residues 
and one lysine (AAAAAAK) and has been reported as an siRNA (small 
interfering RNA) delivery tool [19]. In this work we aimed to demon-
strate a new boron delivery system based on A6K peptide and BSH, and 
open up a novel direction for boron agents in the next generation of 
BNCT. 
2. Materials and methods 
2.1. A6K peptide, boron cluster (BSH), and preparing the A6K/BSH 
complex 
BSH was purchased from KATCHEM (Czech Republic) and A6K 
peptide was kindly provided by 3-D Matrix, Ltd. (Tokyo, Japan). A 10 
mM solution of A6K was prepared in sterilized Milli-Q water using ul-
trasound sonication. 2 M BSH solution was used to prepare different 
ratio mixtures with A6K peptide. 
2.2. Scanning electron microscopy and sample preparation 
A6K/BSH complex mixtures; 1:1 (20 μM A6K/20 μM BSH), 1:2.5 (20 
μM A6K/50 μM BSH, 1:5 (20 μM A6K/100 μM BSH), 1:10 (20 μM A6K/ 
200 μM BSH), 1:20 (20 μM A6K/400 μM BSH), and 1:50 (20 μM A6K/1 
mM BSH) were placed on cover glass (Fisherbrand microscope cover 
glass 18CIRCLE) and allowed to dry naturally on the scanning electron 
microscope (SEM) stage. All samples were observed using SEM at the 
following magnifications; 10,000, 40,000, 80,000, and 200,000 (S- 
4800, Hitachi Power Solutions Co. Ltd). The average diameter of the 
nano-complex was calculated from a total of 50 particles in different 
observation fields. 
2.3. Cell culture of human glioma cell line 
A human malignant glioma cell line—U87 delta EGFR glioma cell 
line, kindly provided by Prof. W. Cavenee and Dr. A. Mukasa (Depart-
ment of Cellular & Molecular Medicine, University of California, San 
Diego, CA, USA)—which stably expresses constitutively active EGFRvIII, 
was used in all experiments. The cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM; Wako) with 10% fetal bovine serum 
(FBS), penicillin, and streptomycin at 37 ◦C in a humidified atmosphere 
containing 5% CO2. 
2.4. Cell proliferation assay (WST-1 assay) 
After the glioma cells (1 × 10 [3]/well) were seeded in 96-well flat- 
bottomed plates, they were cultured in DMEM containing 10% FBS for 
24 h. The cells were then supplemented with different concentrations of 
either A6K/BSH, or A6K peptide, and incubated for a further 24 h. Cell 
viability was measured using the WST-1 (Water-Soluble Tetrazolium) 
assay according to the manufacturer’s instructions (Roche Applied 
Science). 
2.5. Inductively coupled plasma (ICP) measurement of intra-cellular 
boron 
All of the cell samples were measured by ICP (ICP-AES, VISTA-PRO, 
Seiko Instruments Inc.) using a previously described method [9]. The 
intracellular boron concentration (10B ng/106 cells) was calculated from 
the amount of boron present and the cell number of the sample. The ICP 
measurement was overseen by Dr. H. Nagare (Okayama University 
Faculty of Environmental Science and Technology). 
2.6. Immunocytochemistry (ICC) of human glioma cells 
ICC was performed to analyze the distribution of BSH in vitro. The 
anti-BSH mouse antibody was kindly provided by Prof M. Kirihata, 
Osaka Prefectural University. The early endosome marker (CellLight™ 
Early Endosomes-RFP, BacMam 2.0, Thermo Fisher Scientific) was used 
in accordance with the manufacturer’s instructions. The cells were 
cultured on poly-L-lysine coated cover glass (4912–040, IWAKI) with 
BSH or A6K/BSH complex for 0.5, 6, 12, and 24 h. After incubation with 
the boron compounds, the cells were thoroughly washed five times with 
PBS, fixed with 4% paraformaldehyde (PFA) for 30 min, and incubated 
with mouse anti-BSH mAb. The secondary antibody was incubated with 
mouse IgG conjugated Alexa-Fluor 488 for 2 h. Nuclear staining with 
Hoechst 33258 and cytoplasmic staining with Phalloidin 555 were 
carried out for 30 min, and intracellular fluorescence signals were 
observed using a confocal laser microscope (FV1200, Olympus, Japan). 
2.7. Mouse brain tumor model with immunohistochemistry (IHC) and 
pharmacokinetics (PK) 
All animal use and care procedures were approved by the Depart-
ment of Animal Resources, Advanced Science Research Center, 
Okayama University (OKU-2016475, OKU-2019091) and followed all 
required protocols. Athymic mice were used (BALB/C-nu/nu, female, 
6–8 weeks, 16–20 g, Japan SLC, Inc.). After two weeks, BSH (20 mM) or 
A6K/BSH complex (2 mM A6K/20 mM BSH), 10 μL/g (mouse body 
weight), were injected intravenously through the tail vein of the tumor- 
bearing mice for IHC. 12 h after injection, the mice were euthanized, and 
the brains were resected and placed in 10% PFA. Brain sections of 10 μm 
thickness were cut on a microtome (CM 1850; Leica Microsystems, 
Wetzlar, Germany). The IHC was carried out with 4% PFA fixing, 1% 
(w/v) BSA blocking; primary antibodies, anti-BSH antibody—kindly 
provided by Prof. M. Kirihata (Research Center for Boron Neutron 
Capture Therapy, Osaka Prefecture University)—and HLA-A; Secondary 
antibodies, anti-mouse IgG fused Alexa-Fluor 488 and anti-rabbit IgG 
fused Alexa-Fluor 555; and nuclear staining was achieved with Hoechst 
33258. All of the samples were observed using a confocal laser micro-
scope (FV1200, Olympus, Japan). 
In PK, A6K/BSH complex (2 mM A6K/20 mM BSH), 50 mg/kg (BSH/ 
mouse body weight), were injected intravenously through the tail vein 
of the brain tumor-bearing mice. 1 h, 2 h, and 24 h after injection, the 
mice were euthanized, each organ (heart, lung, brain, kidney, liver, 
blood, and brain tumor) was resected. And all samples were measured 
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the weight, completely dissolved with 60% nitric acids and heat treat-
ment, and determined boron concentration with ICP-MS (Agilent tech-
nologies 7500cx, USA) in Institute of Plant Science and Resources 
(IPSR), Okayama University, Japan. 
2.8. Neutron radiation experiment at the Institute for Integrated 
Radiation and Nuclear Science, Kyoto University (KURNS) 
All protocols were approved by the KURNS ethics committee. 24 h 
before neutron irradiation, the U87 delta EGFR cell line was treated with 
200 μM A6K/2 mM BSH (final concentrations) or 100 μM A6K/1 mM 
BSH (final concentrations). Just before neutron irradiation, the cell 
samples were transferred to collecting tubes and subjected to 1 MW 
neutron irradiation (thermal neutron flux 1.4 × 109 neutron/cm2/s) for 
5 min (thermal neutron fluence 4.4 × 1011 neutron/cm2, γ-ray 0.7 ×
10− 1 Gy), 15 min (thermal neutron fluence 1.1 × 1012 neutron/cm2, 
γ-ray 1.7 × 10− 1 Gy), or 30 min (thermal neutron fluence 2.8 × 1012 
neutron/cm2, γ-ray 3.1 × 10− 1 Gy) (Fig. 5A, C, D). In addition, U87 delta 
EGFR were treated with 2 mM BSH; 200 μM A6K/2 mM BSH; or 100 μM 
A6K/1 mM BSH (final concentrations) and subjected to 1 MW neutron 
irradiation at the KURNS facility for 15 min (thermal neutron fluence 
1.1 × 1012 neutron/cm2, γ-ray 2.5 × 10− 1 Gy) and 30 min (thermal 
neutron fluence 2.4 × 1012 neutron/cm2, γ-ray 5.5 × 10− 1 Gy). After 
irradiation, all glioma cells were re-cultured in 96 well plates (9 × 103 
cells/well) for 24 h and 48 h, and cell proliferation was measured with 
Cell Proliferation Reagent WST-1 (Roche, Basel) using a microplate 
reader (Vient XS, DS Pharma Promo Co., Ltd) (Fig. 5B). A colony for-
mation assay was carried out after 2 weeks of culture with U87 delta 
EGFR in 60 mm culture dishes (n = 4) and all culture cells were stained 
with 0.5% Crystal Violet (CV) in 20% methanol. The colonies of CV 
stained samples were counted automatically with an aCOLyte 3 auto-
matic colony counter machine, (Synbiosis, A Division of Synoptics Ltd) 
and all data were statistically analyzed. 
2.9. Zeta potential measurement 
All A6k (0.1 mM, 0.2 mM, and 0.4 mM) and A6K/BSH (0.1 mM/1.0 
mM, 0.2 mM/2.0 mM, and 0.4 mM/4.0 mM) samples were measured 
using a Zetasizer Nano ZSP (N = 9) in accordance with the manufac-
turer’s instructions (Malvern Panalytical). 
2.10. Statistical analysis 
All data are presented as mean ± standard error of the mean (SEM). 
The data were analyzed for statistical significance using Student’s t-test. 
Difference was assessed with a two-side test with an alpha level of 0.05. 
A statistically significant difference was defined as p < 0.05. 
3. Results 
3.1. Scanning electron microscopy images and zeta potential of A6K and 
A6K/BSH complexes 
A6K peptide nanotubes (20 μM) in Milli-Q water were placed on a 
cover glass on an SEM stage and allowed to dry naturally at room 
temperature before osmium evaporation coating. The SEM image of A6K 
peptide nanotubes showed self-assembled tube shapes and with an 
average long dimension of 522.5 ± 92.2 nm and average short dimen-
sion of 229.4 ± 43.9 nm (Fig. 1A, B, Table 1). The magnifying power 
used to acquire the SEM images in Fig. 1C, D, E, L, M, and N was 40,000 
and that for Fig. 1F, G, H, I, J, K, O, P, Q, R, S, and T was 200,000. The 
1:1 mixture ratio of A6K/BSH (20 μM A6K/20 μM BSH) did not show 
individual particles, but continuous dendritic materials (Fig. 1C, F, I), 
and particle size measurement was not possible (Table 1). The 1:2.5 
mixture complex (20 μM A6K/50 μM BSH) showed irregular particles of 
various sizes and the average diameter was 132.6 ± 25.4 nm (Fig. 1D, G, 
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Fig. 1. Scanning electron microscopy imaging of A6K peptide nanotubes and 
different mixture ratios of A6K/BSH complex: (A), (B) SEM images of A6K 
peptide nanotubes, magnification ratio (A) ×10,000, (B) ×80,000. (C)–(T) SEM 
images of A6K/BSH complexes with different mixture ratios of A6K and BSH. 
The upper rows (1-C, D, E, L, M, N) for the A6K/BSH complexes show low 
magnification ×40,000 images and the middle and lower rows (1-F, G, H, I, J, 
K, O, P, Q, R, S, T) show high magnification ×200,000 images. 
Table 1 
List of average particle diameters measured from SEM images (in each case n =
50 ± SD).  
A6K/BSH mixture ratio Average particle diameter (nm) n = 50 
1:1 Impossible to measure 
1:2.5 132.6 ± 25.4 
1:5 73.7 ± 19.9 
1:10 39.3 ± 17.4 
1:20 24.5 ± 3.6 
1:50 18.3 ± 2.5 
A6K peptide nanotube Long diameter 522.5 ± 92.2 
Short diameter 229.4 ± 43.9  
H. Michiue et al.                                                                                                                                                                                                                                
Journal of Controlled Release 330 (2021) 788–796
791
μM A6K/200 μM BSH), 1:20 (20 μM A6K/400 μM BSH), and 1:50 (20 μM 
A6K/1 mM BSH) showed spherical particles in the SEM images and the 
particle diameters were measured to be 18.3–73.7 nm from the SEM 
images acquired using a simple drying method (Fig. 1E, H, K, L, M, N, O, 
P, Q, R, S, T, Table 1). Altering the mixture molar ratio of A6K and BSH 
resulted in different particle shapes and sizes in the SEM images. The 
zeta potential of different concentrations of A6K or A6K/BSH was 
measured using a Zetasizer Nano ZSP. All A6K samples showed positive 
zeta potentials (0.1 mM A6K: +42.6 ± 2.7 mV, 0.2 mM A6K: +48.2 ±
2.4 mV, 0.4 mM A6K: +50.4 ± 1.6 mV). In contrast, all A6K/BSH 
showed negative zeta potentials (0.1 mM A6K/1.0 mM BSH: − 38.2 ±
1.9 mV, 0.2 mM A6K/2.0 mM BSH: − 39.6 ± 2.0 mV, 0.4 mM A6K/4.0 
mM BSH: − 41.3 ± 1.4 mV) (Table 2). 
3.2. Optimization of the mixture ratio of A6K/BSH through evaluation of 
intracellular boron concentration in human glioma cells 
Optimization of the A6K/BSH ratio is essential for boron drug de-
livery systems using A6K peptide nanotubes. BSH and A6K peptide were 
mixed in a tube by gentle pipetting and administered to the glioma 
culture medium. Initially, the BSH concentration was fixed a1t 2 mM in 
the final medium concentration, and the A6K concentration was varied 
to 20, 100, 200, and 400 μM in the final concentration—mixture ratios 
of A6K/BSH of 1:100, 5:100 (1:20), 10:100 (1:10), and 20:100 (1:5), 
Table 2 
List of average zeta potential values measured using a Zetasizer Nano ZSP (in 
each case n = 9 ± SD).  
A6K (mM) 0.1 0.2 0.4 
Zeta potential (mV) +42.6 ± 2.7 +48.2 ± 2.4 +50.4 ± 1.6     
A6K/BSH (mM) mixture ratio 1:10 0.1/1.0 0.2/2.0 0.4/4.0 





































Fig. 2. Intracellular boron concentration and cytotoxicity of 
different mixture ratios of A6K and BSH incubated with U87 
delta EGFR cells for 24 h: (A), (B) Human glioma cells were 
treated with BSH only or different A6K/BSH mixtures. Y-axis 
shows intracellular boron concentration [ng10B/106 cells]. (A) 
The A6K/BSH ratio was altered to give different mixtures with a 
fixed 2 mM BSH concentration. (B) The A6K/BSH ratio was 
altered to give different mixtures with fixed A6K concentrations 
(50 μM, 100 μM, and 200 μM). (C), (D) WST-1 cell proliferation 
assay showing boron drug toxicity with different A6K/BSH 
mixture ratios after 24 h incubation. The mixture ratio was 
designed with constant BSH or A6K concentration. Y-axis shows 
the value of absorbance in the range 450–690 nm measured with 
an absorptiometer.   
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respectively. The most effective intracellular transduction ratio was 
determined by measurement of the intracellular boron concentration of 
U87 delta EGFR using ICP-AES. BSH alone was used as a negative control 
drug that was unable to penetrate cells. The ICP results for different 
mixture ratios of A6K/BSH from 1:100 to 1:5 administered to glioma 
cells, showed 498.9 ± 75.1, 1239.9 ± 177.3, 2606.7 ± 430.0, and 
3846.4 ± 372.6 [ng10B/106 cells] following 24 h culture incubation, 
respectively (Fig. 2A). Analysis of the mixture ratios 1:2.5, 1:5, and 1:10 
with A6K concentrations of 50, 100, and 200 μM showed only small 
differences between the results for 1:5 and 1:10 (Fig. 2B). 
3.3. Cytotoxicity of the A6K/BSH complex determined by cell 
proliferation assay 
All of the complexes were prepared using final concentrations of BSH 
of 2 mM or 200 μM with different A6K peptide concentrations and the 
cell proliferation was measured using the WST-1 assay in U87 delta 
EGFR cells (Fig. 2C, D). Following incubation with the boron complex 
for 24 h, the absorbance in the range 450–690 nm was measured in 96 
well plates following the manufacturer’s instructions (Roche Applied 
Science). None of the A6K/BSH complex treated groups showed any 
difference in cell proliferation to the control group (Fig. 2C, D). The 
A6K/BSH boron drug showed no toxicity after 24 h incubation with U87 
delta EGFR cells. 
3.4. Intracellular boron concentration over time following administration 
of A6K/BSH complex and immunocytochemistry imaging of BSH 
localization 
The intracellular boron concentration of U87 delta EGFR cells was 
measured by ICP-AES, and the final medium concentration of each 
boron drug was 2 mM BSH or 200 μM A6K/2 mM BSH complex. Each 
sample was analyzed for boron concentration 0.5, 1, 4, 6, 12, and 24 h 
after continuous incubation (Fig. 3A). The A6K/BSH group showed 
significantly higher intracellular boron concentration (1425.2 ± 131.5 
[ng10B/106 cells]) than that of the BSH group (155.7 ± 7.1 [ng10B/106 
cells]) 0.5 h after sample administration. Following 1, 4, 6, 12, and 24 h 
of incubation with A6K/BSH cells showed 3272.6 ± 699.4, 3601.3 ±
598.9, 3995.8 ± 263.0, 4223.2 ± 679.9, and 5604.9 ± 78.1 [ng 10B/106 
cells] and those incubated with BSH showed 218.8 ± 19.0, 318.3 ± 46.5, 
358.5 ± 56.6, 318.0 ± 34.4, and 536.0 ± 61.7 [ng 10B/106 cells], 
respectively. The A6K/BSH group showed approximately 10–15 times 
higher boron concentrations in U87 delta EGFR glioma cells over the 
time course. We subsequently observed intracellular BSH localization by 
immunocytochemistry with BSH antibody (green), phalloidin (f-actin, 
red), and Hoechst (nuclear marker, blue) after administration of the 
boron agents for 0.5, 6, 12, and 24 h. In the 6 h A6K/BSH group, BSH 
was observed in the cytoplasmic region and in the 12 and 24 h groups, 
the BSH signal was clearly seen in the cell and observed particularly 
strongly in the perinuclear region (Fig. 3B). 
To evaluate the cytoplasmic localization with A6K/BSH complex in 
the 24 h group, early endosome marker (CellLight™ Early Endosomes- 
RFP, BacMam 2.0, Thermo Fisher Scientific), BSH antibody, and nu-
clear staining were used (Fig. 3C). The acquired image shows that BSH 
localized in endosomes after transduction into cells. All of the data 
indicated the intracellular transduction of A6K/BSH through 
endocytosis. 
3.5. Immunohistochemistry observation and pharmacokinetic study with 
A6K/BSH complex administration in a mouse brain tumor model 
The mouse brain tumor model was established using U87 delta EGFR 
cells over a 2-week period. In IHC, mice were administered A6K/BSH 
complex (A6K 2 mM/BSH 20 mM in MilliQ water, 10 μL/mouse body 
weight [g]) through the tail vein. 12 h after injection, mice were 
euthanized, a brain tumor sample was taken and the BSH localization in 
vivo was evaluated using immunohistochemistry. Under low magnifi-
cation (×10), A6K/BSH was observed in the tumor area and peripheral 
tumor area. In contrast, the brain of the mouse administered BSH alone 
showed no BSH signal in the normal tissue or tumor areas. At high 
magnification (×40), the A6K/BSH group showed BSH localized at the 
tumor core and tumor edge area, but not in normal brain tissue. In PK 
study, In PK, A6K/BSH complex (50 mg/kg, BSH/mouse body weight), 
were injected intravenously through the tail vein of the brain tumor- 
bearing mice. In 1 h, 2 h, and 24 h after injection, each organ (heart, 
lung, brain, kidney, liver, blood, and brain tumor) was measured boron 
concentration with ICP-MS (Fig. 4D). The boron concentration in brain 
tumor reached resected 19.7, 24.8, and 8.9 μg 10B/tissue g, in 1 h, 2 h, 
and 24 h (Fig. 4D). The brain tumor/normal brain (T/N) ratio was 6.8, 
2.8 and 40 (Fig. 4D). These data showed that A6K/BSH accumulated in 
the tumor and peripheral tumor area as a result of the complexation. 
3.6. The boron neutron reaction using neutron irradiation at KURNS 
We evaluated the in vitro cell killing effect of the boron neutron re-
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Fig. 3. The intracellular boron concentration and boron localization with 
complex A6K (200 μM)/BSH (2 mM) over time: (A) Comparison of BSH with the 
A6K/BSH complex for different incubation times (0.5, 1, 4, 6, 12, and 24 h). Y- 
axis shows the intracellular boron concentration [ng10B/106 cells]. (B) Confocal 
laser microscopy images of intracellular localization of BSH in human glioma 
cells over time (0.5, 6, 12, and 24 h). The red signal is F-actin labeled with 555 
phalloidin, the green signal is BSH labeled with BSH antibody, and the blue 
signal is nuclei labeled with Hoechst 33258. (C) Intracellular co-localization of 
BSH and the endosome in U87 delta EGFR cells using endosome marker 
(CellLight™ Early Endosomes-RFP) in 6 and 24 h. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
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Kyoto University (KURNS). The U87 delta EGFR cell line was treated 
with 100 μM A6K/1 mM BSH or 200 μM A6K/2 mM BSH 24 h before 
neutron irradiation. Following 1 MW neutron irradiation for 5 min 
(thermal neutron fluence 4.4 × 1011 neutron/cm2, γ-ray 0.7 × 10− 1 Gy), 
15 min (thermal neutron fluence 1.1 × 1012 neutron/cm2, γ-ray 1.7 ×
10− 1 Gy), and 30 min (thermal neutron fluence 2.8 × 1012 neutron/cm2, 
γ-ray 3.1 × 10− 1 Gy) at KURNS (thermal neutron flux 1.4 × 109 neutron/ 
cm2/s), we carried out a cell proliferation assay (WST-1 assay) over 48 h 
and colony formation assay over 14 days (Fig. 5A, C, D). Fig. 5B shows 
the WST-1 assay results for U87 delta EGFR after 24 h and 48 h, 
following 1 MW neutron irradiation at KURNS for 15 min (thermal 
neutron fluence 1.1 × 1012 neutron/cm2, γ-ray 2.5 × 10− 1 Gy), or 30 
min (thermal neutron fluence 2.4 × 1012 neutron/cm2, γ-ray 5.5 × 10− 1 
Gy). No significant differences were observed for the control group for 
any radiation time (Fig. 5A). In contrast, the 100 μM A6K/1 mM BSH 
and 200 μM A6K/2 mM BSH groups showed inhibition of cell prolifer-
ation dependent on neutron radiation dose and irradiation time 
(Fig. 5A). The WST-1 assay results indicate an acute cell death reaction 
48 h after the boron neutron reaction. In addition, the colony formation 
assay carried out 14 days after the boron neutron reaction showed late 
and slow cell reaction (Fig. 5C, D). The control groups were exposed to 
neutron irradiation without boron drug. The number of colonies formed 
in the control group showed little change with exposure time. However, 
the colony formation assay for the A6K/BSH complex groups—100 μM 
A6K/1 mM BSH and 200 μM A6K/2 mM BSH—showed survival ratios of 
1, 0.78, 0.39, and 0.08 and 1, 0.27, 0.10, and 0.03, for 0, 5, 15, and 30 
min neutron irradiation periods, respectively (Fig. 5C, D). The group 
treated with BSH only showed ratios of 1, 0.65, and 0.5 for 0, 5, and 15 
min neutron irradiation periods. In the colony formation assay, the 
suppressive effect was clear for both A6K/BSH complex groups with 
thermal neutron irradiation dose escalation (Fig. 5D). Compared with 
the 2 mM BSH treated group, the A6K/BSH complex groups showed 
inhibition of cell proliferation following 15 min and 30 min neutron 















































Fig. 4. The systemic administration of A6K/BSH 
complex in a mouse brain tumor model for IHC and 
PK: (A) Schematic illustration of boron drug systemic 
administration through mouse tail vein for treating a 
mouse brain tumor model. (B)(C) The immunohisto-
chemistry imaging of mouse brain tumor model 
samples 12 h after mouse tail vein injection of BSH 
(20 mM) or A6K/BSH complex (2 mM A6K/20 mM 
BSH), 10 μL/g (mouse body weight). The red signal is 
anti-human HLA-A antibody, the green signal is BSH 
labeled with BSH antibody, and the blue signal is 
nuclei labeled with Hoechst 33258. Scale bars; (B) 
300 μm and (C) 50 μm. (D) The pharmacokinetic (PK) 
study with mouse brain tumor model in 1 h, 2 h and 
24 h with mouse tail vein injection of A6K/BSH 
complex (2 mM A6K/20 mM BSH), 50 mg/kg (BSH 
/mouse body weight). Tissue 10B concentration 
(μg10B/tissue g) of all samples measured by ICP-MS. 
(For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version 
of this article.)   
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4. Discussion 
Numerous potential boron delivery systems based on macromolec-
ular aggregates have been reported in the BNCT research field, partic-
ularly liposomes and water-in-oil-in-water (W/O/W) emulsions 
[20–23]. Small unilamellar liposomes composed of a pure synthetic 
phospholipid and cholesterol encapsulating water-soluble ionic boron 
compounds (B10H10(2-), B12H11SH2-, B20H17OH4-, B20H19(3-), 
B20H18(2-)); distearoylphosphatidylcholine (DSPC) liposomes and 
DSPC–PEG liposomes with nido-carborane lipid; and small, unilamellar 
BSH-encapsulating, transferrin (TF)-conjugated polyethyleneglycol li-
posomes (TF-PEG liposomes) as colon cancer and brain tumor targeting 
system have been reported [24–26]. However, several challenges 
relating to low toxicity with mass administration, drug stability of the 
encapsulated boron compounds, and tumor-specific accumulation, 
remain barriers to the practical application of boron drugs with 
macromolecular DDS for clinical BNCT [27]. 
Our peptide DDS concept is different to the conventional boron drug 
delivery systems previously described [19,28]. In the development of 
modern peptide chemistry, several short peptides have been found to 
exhibit various morphological structures and to be appropriate for use as 
drug delivery tools [29]. The lipid-like self-assembly of short peptides 
into nanotubes is a ubiquitous phenomenon. One of the leading lipid- 
like peptide nano-vesicle systems is the A6K nanotube [28,29]. The 
A6K peptide is an amphiphilic peptide that contains a cationic amino 
acid. In water, A6K easily forms luminal macaroni shapes, exposing 
lysine at the surface of the peptide nanotube [30]. The lipid-like self- 
assembling peptide A6K is therefore a suitable carrier for negatively 
charged drugs. The A6K drug delivery method is currently used for 
nucleic acid medicine and an A6K/siRNA complex has been investigated 
as a new drug against breast cancer at the National Cancer Center Japan 
[19,31,32]. 
A major advantage of the new A6K/BSH boron drug is the simple 
mixing of A6K peptide and BSH solution to make up the complex just 
before drug use without complicated drug adjustment steps [33]. In a 
recently published example focusing on the widely used drug BPA, poly 
control
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Fig. 5. The boron neutron reaction in vitro with low or 
high dose A6K/BSH complex in U87 delta EGFR cells 
analyzed at KURNS: (A)(B) Cell proliferation by WST-1 
assay after 24 and 48 h incubation for different 
neutron irradiation times (1 MW; 0, 5, 15, and 30 min), 
y-axis shows the value of absorbance in the range 
450–690 nm measured with an absorptiometer. (C)(D) 
U87 delta EGFR cell colony formation assay with CV 
staining after 14 days for different neutron irradiation 
times (black line: control group, gray line: 2 mM BSH, 
blue line: low dose 100 μM A6K/1 mM BSH, and orange 
line high dose 200 μM A6K/2 mM BSH, in each case n =
4). (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of 
this article.)   
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(vinyl alcohol) (PVA) was shown to readily form complexes with BPA 
through reversible boronate esters and the complex of PVA-BPA showed 
strong tumor accumulation in a mouse model [33]. This PVA-BPA 
complex demonstrates the clinical relevance of BNCT delivery systems 
whose preparation can be easily translated for practical use. The 
development of new boron agents for clinical application is expensive 
and time consuming. However, the A6K peptide delivery tool is in the 
clinical trial stage and BSH has been a BNCT clinical trial drug for ma-
lignant brain tumor treatment for a long time. Both drugs have been 
confirmed as safe and stable for clinical use. In this paper, A6K/BSH 
complex showed high tumor specific accumulation in IHC, high T/N 
ratio (2.5 time or more) and high boron concentration (20 ppm 10B or 
more) in mouse brain tumor in PK study. The A6K/BSH complex is of 
course a new drug requiring preclinical testing; however, the barriers to 
its use may be lower based on the safety of its components. 
In this work we chose an A6K/BSH mixture ratio of 1:10, therefore 
A6K peptide was added to BSH solution at 10% molar concentration and 
mixed gently by pipetting. The addition of an A6K supplement to a BSH 
solution to prepare a new boron drug is both innovative and simple in 
terms of drug design, and provides a different approach to those previ-
ously explored in the conventional boron DDS field. Because BSH is a 
negatively charged compound and A6K is a positively charged peptide, 
the two drugs easily formed a complex through electrostatic interaction 
[34]. Indeed, several studies have reported the mechanism of A6K/ 
siRNA complex formation on the same principle. In the future, when 
there are potentially many negatively charged boron compounds, new 
boron complexes with A6K nanotubes can be investigated for intracel-
lular transduction for BNCT. 
The mechanism for A6K/BSH complex transduction into cells is 
thought to be endocytosis because many previous reports have found 
that A6K/siRNA enters the cell via endocytosis. The surfaces of A6K/ 
material complexes have a positive charge, and the electrostatic inter-
action between the complex surface and the negatively charged cell 
membrane causes attachment of the drug to the cell before endocytosis 
[34]. Other DDS tools, such as liposomes, have several limitations in 
terms of the encapsulation of boron drugs inside the particles; however, 
the A6K/BSH system shows facile drug encapsulation [35]. This work 
has demonstrated that a new BSH compound—BSH supplemented with 
A6K peptide at 10 mol%—is a new potential candidate for the next 
generation of boron drugs. The precise mechanism for the cell uptake of 
the new boron complex requires further investigation. However, our 
experimental results demonstrate the potential clinical relevance of 
combining a peptide DDS with the boron drug BSH. 
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